A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

• Status: Terminated
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atorvastatin; Atorvastatin Calcium; Evacetrapib; Ezetimibe

Criteria

Inclusion Criteria:

• Must be treated with atorvastatin 40 mg/day for at least 30 days prior to screening

• Have an LDL-C >70 mg/deciliter(dL) or non-HDL-C >100 mg/dL

• Have screening triglycerides ≤400 mg/dL (≤4.5 millimoles/Liter)

• Individuals with ASCVD and/or individuals with type 1 or type 2 diabetes

Exclusion Criteria:

• Have a hemoglobin A1c (HbA1c) >9.5%

• New York Heart Association (NYHA) class III or IV congestive heart failure

• History of either a transient ischemic stroke or ischemic stroke <30 days

• History of acute coronary syndrome (ACS) <30 days